China - Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company')'s licensing partner Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ('Calliditas') announced that the U.S. Food and Drug Administration (FDA) had approved Nefecon delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

Nefecon was first approved in December 2021 under the FDA accelerated approval pathway and is now the first fully FDA-approved treatment for IgAN based on a measure of kidney function.

The FDA approval is for adults with primary IgAN who are at risk for disease progression, irrespective of proteinuria levels.

Nefecon is now approved by the FDA with a confirmed and statistically significant benefit over placebo (p

(C) 2023 Electronic News Publishing, source ENP Newswire